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Abstract
Cell‐processing procedures are conducted in accordance with Good Manufacturing 
Practices, and clinical procedures are performed by highly optimised methods. A high‐
quality transportation system is essential for safe and effective handling of mesenchy‐
mal stem cells (MSCs) between cell‐processing and transplantation stages. For MSC 
transportation, either frozen cell or non‐frozen cell transportation is performed. There 
are many requirements for transporting a package by either type of transportation. In 
frozen cell transportation, some issues have yet to be resolved: the primary receptacle 
and cryoprotectant reagents. In non‐frozen cell transportation, control of cell metabolism 
and protection from environmental changes are more serious problems. Stabilisation of 
temperature, shock resistance, gas control, and an ultraviolet radiation (UVR) shield‐
ing technology should be considered. The transportation system should be established 
in compliance with the guidelines. Both development of a high‐quality transportation 
package and establishment of a high‐quality transportation system are important for the 
effective use of MSCs in clinical applications.
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1. Introduction
Cell‐processing procedures are conducted in accordance with Good Manufacturing Practices, 
and clinical procedures such as transplantation and infusion are performed using highly 
optimised techniques [1]. Thus, a high‐quality transportation system is necessary for safe 
and effective handling of materials and mesenchymal stem cell (MSC) products between 
cell‐processing and transplantation stages. Frozen cell transportation is conventionally used 
in laboratories. Nonetheless, there may be some disadvantages of this method for clinical 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
applications. For example, the tubes usually used for frozen transportation are not com‐
pletely sealed receptacles, and the cryoprotection reagents have some effects on the human 
body. In non‐frozen cell transportation, control of cell metabolism and protection from envi‐
ronmental changes are serious problems. A transportation system should be established to 
prevent man‐made incidents. In this study, the elements required for transportation of MSCs 
are discussed.
2. Conditions required for MSC transportation
There are many possible scenarios of MSC transportation. When the MSCs are isolated imme‐
diately from materials in a hospital, establishment of a transportation system inside the hos‐
pital is needed (Figure 1A). If further manipulation of MSCs or mass culture is performed, 
MSC materials such as bone marrow, cord blood, and adipose tissue are transported from the 
Figure 1. The scenarios of MSC transportation. (A) Extraction of materials in a hospital. (B) Extracted materials are 
transported to a cell‐processing centre, and MSC products are transported to the hospital. (C) In some cases, MSCs are 
stored in a cell bank.
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hospital to a cell‐processing centre (CPC). At a CPC, the materials are cultured and manipulated 
and then transported to the hospital (Figure 1B). These transportation scenarios (Figure 1A, B) 
work effectively with autogenic transplantation. When allogeneic transplantation is performed, 
some temporary storage is used. In such cases, other facilities such as cell banks or stock houses 
are added [2] (Figure 1C).
Basically, when the transportation is performed within a hospital, there are not many require‐
ments for the transportation package and transport system if a good environment is main‐
tained in the hospital. Some packaging technology is needed when outside transportation is 
performed among a hospital, CPC, and cell bank (Figure 1B, C). In the outside environment, 
the transported materials and MSC products should be protected from some external envi‐
ronmental factors such as micro‐organisms, temperature, shocks, humidity, ultraviolet radia‐
tion (UVR), and atmospheric pressure. The transportation package should withstand such 
external environmental stimuli.
3. Requirements for transportation and three‐level packaging
There are some requirements for transportation of MSCs for clinical use:
• Leakproofness
• Sterility
• Temperature stabilisation
• Shock resistance
• Gas stability
• UV shielding
• Monitoring
Each requirement is important, but the degree of importance is different in each transporta‐
tion scenario (Figure 1, Table 1). A single type of package cannot fulfil all the requirements. 
A three‐level packaging system is recommended by the World Health Organisation (WHO) 
[3] (Figure 2). Each package satisfies each requirement. Tests required for compliance with 
the criteria include a 9‐m drop test, a puncture test, and a stacking test for the packages [3].
3.1. The primary receptacle
The materials and the cell products are inserted into the first package. The primary receptacle 
should be completely sealed to prevent invasion of micro‐organisms and leakage of contents. 
The materials constituting the primary receptacle should be chosen carefully to prevent elu‐
tion of chemical materials. Packaging the contents into the primary receptacle is performed in 
the CPC area, and the primary receptacle should be sterilised.
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3.2. The second package
The primary receptacle is inserted into the second package (Figure 2). Sterilisation treatment 
of the second package is not necessary if the complete sterilisation and sealing are achieved 
for the primary receptacle. Some materials for absorbing liquids are needed if the first recep‐
tacle is broken and the contents leak out. A shock absorber and temperature control system 
such as materials for hot storage are included in the second package. For monitoring the tem‐
perature and shocks, a sensing device is also included.
Sterility Shock resistance Temperature 
stabilisation
Monitoring
Inside hospital ✓✓ ✓ ✓ ✓
From hospital to CPC 
(materials)
✓✓ ✓✓ ✓✓ ✓✓
From CPC to hospital (products)
Non‐frozen ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓
Frozen ✓✓ ✓ ✓✓ ✓
From cell bank to hospital (products)
Non‐frozen ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓
Frozen ✓✓ ✓ ✓✓ ✓
From stockhouse to hospital (products)
Non‐frozen ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓
Frozen ✓✓ ✓ ✓✓ ✓
MSC, mesenchymal stromal cell; CPC, cell‐processing centre.
Table 1. Technologies needed for each processing scenario of MSC materials and products.
Figure 2. A three‐level packaging system of a transportation box in regenerative medicine.
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3.3. The outer package
The second package is placed into the outer package (Figure 2). The outer level is the packag‐
ing most exposed to external environmental stimuli. The characteristics of heat insulation, 
toughness, waterproofness, and UV shielding are necessary. For the handling, slings and belts 
are attached to the outer package. A notice, security lock, and invoice are attached as acquired.
4. Requirements for the packages
4.1. Leakproofness
Tight sealing is required from the standpoint of leakproofness and sterility. According to 
the ‘Guidance on Regulations for the Transport of Infectious Substances’, leakproofness is 
required in the primary receptacle and second package [3]. The guidance itself is used for 
transportation of ‘infectious substances’, but it defines the ‘patient specimens’ and ‘bio‐
logical products’ as ‘infectious substances’. Thus, this guidance is to be used as a reference. 
If the primary receptacle loses leakproofness and springs a leak, some absorbent materials 
in the second package should absorb all fluid [3]. Whatever the intended temperature of 
the consignment, the primary receptacle and secondary package should withstand (with‐
out leakage) the internal pressure no less than 95 kPa in the range of temperatures from 
‐40 to +55°C [3].
4.2. Sterility
The importance of sterility does not need to be explained. To guarantee sterility, the primary 
receptacle should be completely sealed. Therefore, the semi‐closed cap‐type receptacle typi‐
cally used for frozen transportation is not recommended as a primary receptacle. Besides, the 
primary receptacle itself should be sterilised.
4.3. Temperature stabilisation
Stabilisation of temperature is employed to control cell metabolism and to prevent degrada‐
tion of cells and products. There are two categories for temperature stabilisation: frozen cell 
or non‐frozen cell transportation.
In the field of frozen cell transportation, research and development on the freezing procedure 
are conducted for the purpose of storage. The success of frozen cell transportation and stor‐
age depends on the temperature control and cryoprotective agents [4]. According to Hubel, 
understanding the mobility of water is paramount for good insight into biochemical reactions 
during freezing [4]. The temperature dependence of protein activity obeys the Arrhenius 
equation [4, 5]:
  K = A ⋅  e −Ea/(RT) (1)
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where k is the rate constant, T is the absolute temperature (Kelvins), A is the pre‐exponential 
factor, E
a
 is the activity energy for the reaction (Joules), and R is the universal gas constant. The 
optimal temperature for transportation and storage should be selected below the threshold 
temperature to manage activity of a protein [4]. Distinct changes are observed near ‐53°C [6, 7]. 
A substrate fails to bind to ribonuclease A at ‐58°C [8]. Some authors reported that activity of β‐
glucosidase is observed even at ‐70°C [9, 10]. These results suggest that a trace protein activity 
may persist even at a low temperature, below ‐80°C [4]. To stabilise proteins and minimise cell 
dehydration, pharmaceutical agents are used for cryoprotection. Cryoprotectants are classified 
into permeating and non‐permeating agents depending on their ability to cross the cell mem‐
brane [11, 12]. The permeating cryoprotectants, such as dimethyl sulphoxide (DMSO), are 
used for clinical preservation and banking of MSCs for the treatment of graft‐versus‐host dis‐
ease (GVHD) [13]. The International Stem Cell Initiative (ISCI) recommends the use of dry 
shippers involving liquid nitrogen (‐196°C) for frozen stem cell transportation [2]. Nonetheless, 
some issues should be resolved regarding cryopreservation and frozen cell transportation. A 
significant loss of living cells after recovery occurs after cryopreservation. The proportion of 
apoptotic and senescent cells increases during cryopreservation in comparison with fresh live 
culture [14–16]. Not only cell viability but also alteration of MSC characteristics is to be consid‐
ered. Immunosuppressive properties of MSCs are altered after cryopreservation although these 
alterations may be favourable for the treatment of GVHD [17, 18]. DMSO is the most widely 
used cryoprotectant in the world, but it has some adverse effects on patients such as nausea, 
headache, hypotension, hypertension, and diarrhoea [19]. Further research and development 
on cryoprotectants, freezing and thawing technologies, cell containers, the primary receptacle, 
and administration method are needed for frozen cell transportation.
In non‐frozen cell transportation, control of cell metabolism is compromised. There is little 
information about the non‐frozen cell transportation of MSCs. Information on the storage of 
platelets serves as a useful reference. Platelets are stored between 20 and 24°C with continu‐
ous agitation, suspended in plasma with a citrate‐based anticoagulant [20]. Platelets at 4°C 
undergo a shape change, α‐granule release, aggregation, apoptosis, and a significant reduc‐
tion of the lifespan. When MSCs that are detached from a culture dish are incubated at 4, 
20, or 37°C in a culture medium for 24 h, the living cell numbers after 37°C incubation are 
higher. Nevertheless, dead cell numbers increase after 37°C incubation (Figure 3). This result 
shows that cell metabolism is not sufficiently controlled during 37°C incubation. The devel‐
opment of a preservation solution and verification of suitable temperature are necessary for 
non‐frozen‐MSC transportation.
4.4. Shock and vibration resistance
There is little or no information about the bioresponse of MSCs to shocks and vibration dur‐
ing transportation. One study evaluated the shocks and vibration associated with truck and 
railway transportation [21]. Peak shock acceleration for the longitudinal axis was 2.8g, for 
the transverse axis 2.3g, and for vertical axis 7.0g on a truck, and all axes were 4.7g on a train 
when a 22‐ton cargo was transported [22]. Peak vibration acceleration for the longitudinal 
axis was 0.27g; for the transverse axis, it was 0.27g; and for the vertical axis, 0.52g on a truck. 
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The frequency range was 0–1900 Hz [22]. Peak vibration acceleration for the longitudinal axis 
was 0.10g, transverse axis 0.19g, and vertical axis 0.52g on a train. The frequency range was 
0–750 Hz [23]. Strong shocks should be prevented from destroying the extracellular matrix 
of products. Microvibration should be considered for prevention of changes in the charac‐
teristics of MSCs. The lipid membrane, primary cilium, extracellular matrix, and intracel‐
lular cytoskeleton respond to mechanical stimuli. They transduce mechanical stimuli via ion 
channels, integrins, and focal adhesion kinase and thus alter gene expression and protein 
synthesis. As a consequence, survival, apoptosis, proliferation, and differentiation proper‐
ties are affected [24]. For example, MSCs were stimulated by vibration from 1 to 1000 Hz, 
and myogenic transcription factors were found to be upregulated by low frequencies (1 and 
50 Hz), but osteogenic transcription factors were upregulated by high frequencies (500 and 
1000 Hz) [25]. These data suggest that some shock absorber is needed to prevent the shocks 
and vibration.
4.5. Gas stability
In frozen‐MSC transportation, gas control is not needed, but in non‐frozen‐MSC transporta‐
tion, some gas control technology is necessary. When we consider the gas control, the knowl‐
edge about cellular senescence is crucial. Cellular senescence was discovered in the 1960s by 
Hayflick [26]. He showed that human diploid fibroblasts have a limited ability to proliferate; 
it is called senescence in ex vivo culture [26]. Some stressors, such as dysfunctional telomeres, 
Figure 3. The cell number of MSCs peeled from a culture dish and incubated at 4, 20, or 37°C in a culture medium for 
24 h. Living cell and dead cell numbers were determined by means of the Live/Dead Staining Kit II (Takara Bio Inc., 
Shiga, Japan).
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genotoxic stressors, DNA damage, UVR, and oxidative stress, induce cellular senescence [27]. 
This phenomenon is induced by the upregulation of p16INK4A in MSCs [28]. The expression of 
p16INK4A is associated with oxidative stress. When MSCs are cultured under hypoxic conditions 
(1% pO
2
), their proliferation is increased by 8–20 population doublings as compared with nor‐
moxic conditions (20% pO
2
) [29]. The p16INK4A gene is downregulated in hypoxic culture [29]. 
An antioxidant agent that induces 5% pO
2
 conditions [30] and 3% hydrogen gas treatment 
[31] prolongs the replicative lifespan. Not only cellular proliferation but also the character‐
istics of MSCs are influenced by gas conditions. The osteogenic differentiation potential is 
not influenced, but adipogenic and chondrogenic differentiation abilities are enhanced under 
hypoxic culture conditions [29]. Cell surface antigens are downregulated, and the ability to 
suppress T‐cell proliferation is diminished by oxidative stress [32]. These results suggest that 
some gas control system is required for non‐frozen‐MSC transportation.
4.6. UVR shielding
UVR is a natural component of sunlight and is invisible to the human eye. There are three types 
of UVR by wavelength: UV‐A (315–400 nm), UV‐B (280–315 nm), and UV‐C (100–280 nm). 
UV‐A and UV‐B can reach the Earth's surface, but the ozone layer filters out UV‐C [33]. Ageing 
of skin associated with UVR exposure is referred to as photoageing. Sun‐exposed areas of the 
skin, such as the face and neck, undergo premature ageing [33]. UV‐A induces production of 
reactive oxygen species (ROS) and activates cell cycle checkpoint proteins such as p53 and p21 
[34]. UV‐B exposure causes structural rearrangement of nucleotides that leads to defects in 
DNA strands. The UVR‐induced ROS production and DNA damage to epidermal stem cells 
lead to photoageing [33]. Although there are many reports about the harmful effects of UVR 
on epidermal stem cells, there is little information about UVR effects on MSCs. The report on 
the gene expression profile, when MSCs were exposed to low‐dose UV‐B, showed that only 
a minimal change in gene expression was induced [35]. Further research is needed and some 
UVR shielding technology may be required, especially in case of air transportation.
4.7. Monitoring
Temperature data loggers are required for proof that transportation was completed without a 
problem. In the absence of temperature data loggers, consideration should be given to the use of 
chemical or other indicators to provide information on temperature during transportation [2]. 
If the shock resistance, gas control, and UV shielding are crucial for the transportation of MSCs, 
then acceleration sensors, gas monitoring, and radiation monitoring should be considered.
5. Transportation systems
Establishment of a transportation system is required in compliance with the government reg‐
ulations in each country and international guidelines. At present, there is no specific guidance 
on transportation for regenerative medicine. Nonetheless, some guidelines issued by the ISCI 
[2] and WHO [3] and specific legislation in Europe [36] can be used for reference.
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Education of delivery personnel to prevent man‐made incidents, preparation of the documen‐
tation for clearance, a traceability system, and security control should be provided. Further 
research and consensus guidelines are needed for the transportation of materials related to 
MSCs and cell products for clinical use.
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